WAVERLEY PHARMA INC (WAVE.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:WAVE - CA94357L1058 - Common Stock
WAVE.CA Key Statistics, Chart & Performance
The current stock price of WAVE.CA is 0.02 CAD. In the past year, price decreased by -20%.
WAVE.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 432.55M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 367.23M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 178.73M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 131.79M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24 | 53.03M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 33.04M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.42M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 29.70M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 15.08M | ||
| MPH.CA | MEDICURE INC | N/A | 13.99M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.22M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 5.92M |
Related stock screener links
About WAVE.CA
Company Profile
Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2017-04-27. The company is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. The company has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. The company also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Company Info
WAVERLEY PHARMA INC
4-1250 Waverley Street
Winnipeg MANITOBA R3T 6C6 CA
CEO: Larry Thiessen
Employees: 0
Phone: 12049287907
WAVERLEY PHARMA INC / WAVE.CA FAQ
What does WAVERLEY PHARMA INC do?
Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2017-04-27. The company is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. The company has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. The company also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
What is the current price of WAVE stock?
The current stock price of WAVE.CA is 0.02 CAD. The price increased by 33.33% in the last trading session.
What is the dividend status of WAVERLEY PHARMA INC?
WAVE.CA does not pay a dividend.
How is the ChartMill rating for WAVERLEY PHARMA INC?
WAVE.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for WAVE stock?
WAVERLEY PHARMA INC (WAVE.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.01).
Can you provide the market cap for WAVERLEY PHARMA INC?
WAVERLEY PHARMA INC (WAVE.CA) has a market capitalization of 1.08M CAD. This makes WAVE.CA a Nano Cap stock.
What is the ownership structure of WAVERLEY PHARMA INC (WAVE.CA)?
You can find the ownership structure of WAVERLEY PHARMA INC (WAVE.CA) on the Ownership tab.
WAVE.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to WAVE.CA. When comparing the yearly performance of all stocks, WAVE.CA is a bad performer in the overall market: 84.88% of all stocks are doing better.
WAVE.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to WAVE.CA. WAVE.CA may be in some trouble as it scores bad on both profitability and health.
WAVE.CA Financial Highlights
Over the last trailing twelve months WAVE.CA reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS increased by 82.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.02% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |